Parallel gradients in FENO and in the prevalences of asthma and atopy in adult general populations of Sweden, Finland and Estonia : A Nordic EpiLung study by Lassmann-Klee, Paul et al.
Respiratory Medicine 173 (2020) 106160
Available online 17 September 2020
0954-6111/© 2020 Elsevier Ltd. All rights reserved.
Original Research 
Parallel gradients in FENO and in the prevalences of asthma and atopy in 
adult general populations of Sweden, Finland and Estonia — A Nordic 
EpiLung study 
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Skin prick test 
A B S T R A C T   
The prevalence of asthma is higher in Sweden and Finland than in neighbouring eastern countries including 
Estonia. Corresponding difference in bronchial eosinophilic inflammation could be studied by FENO measure-
ments. We aimed to compare FENO in adult general populations of Sweden, Finland, and Estonia, to test the 
plausibility of the west-east disparity hypothesis of allergic diseases. 
We conducted clinical interviews (N = 2658) with participants randomly selected from the general pop-
ulations in Sweden (Stockholm and Örebro), Finland (Helsinki), and Estonia (Narva and Saaremaa), and per-
formed FENO (n = 1498) and skin prick tests (SPT) in 1997–2003. 
The median (interquartile range) of FENO (ppb) was 15.5 (9.3) in Sweden, 15.4 (13.6) in Finland and 12.5 (9.6) 
in Estonia. We found the lowest median FENO values in the Estonian centres Saaremaa 13.1 (9.5) and Narva 11.8 
(8.6). In the pooled population, asthma was associated with FENO ≥25 ppb, odds ratio (OR) 3.91 (95% confidence 
intervals: 2.29–6.32) after adjusting for SPT result, smoking, gender and study centre. A positive SPT test 
increased the likelihood of asthma OR 3.19 (2.02–5.11). Compared to Saaremaa, the likelihood of having asthma 
was higher in Helsinki OR 2.40 (1.04–6.02), Narva OR 2.45 (1.05–6.19), Örebro OR 3.38 (1.59–8.09), and 
Stockholm OR 5.54 (2.18–14.79). 
Abbreviations: CI, 95% confidence interval; FENO, Fractional exhaled nitric oxide; FEV1, Forced expiratory volume in 1 s; IQR, Interquartile range; OR, Odds ratio; 
SPT, Skin pick test. 
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There was a higher prevalence of asthma and allergic airway inflammation in adult general populations of 
Sweden and Finland compared to those of Estonia. Atopy and elevated FENO level were independently associated 
with an increased risk of asthma. In conclusion, the findings support the earlier west-east disparity hypothesis of 
allergic diseases.   
1. Introduction 
Asthma is an ubiquitous chronic pulmonary disease with a high 
prevalence mainly in westernised countries, posing an economic burden 
to public health [1]. A major increase in asthma was observed during the 
second half of the past century [2], including Scandinavian countries 
such as Finland [3]. Although this rise seems to have reached a plateau 
in Finland during the recent years [4], the rise has apparently continued 
in northern [5] and western Sweden [6]. Additionally, worldwide, the 
prevalence of asthma still seems to be increasing [7], with hundreds of 
millions globally afflicted [8]. Neighbouring countries of Finland — 
Estonia and Russia — have been less affected with asthma [9,10]. In 
Estonia, a slow increase in asthma prevalence started in the last decades 
of the past century [11]. 
Early hypotheses proposed a west–east disparity in allergic diseases, 
including rhinitis, atopic eczema, and asthma [10,12,13]. Previous 
studies have shown differences in prevalence, but also in diagnostic 
criteria [14], as well as differences in exposure and risk factors between 
countries in eastern and western parts of northern Europe [15]. Re-
searchers in Finland, Sweden and Estonia designed, in the mid-1990s, a 
multi-centre epidemiological study (FinEsS) to investigate allergic and 
obstructive respiratory diseases. A key target of the FinEsS study was to 
find out whether regional differences in the prevalence of asthma were 
reflected in regional differences of fractional exhaled nitric oxide (FENO), 
a biomarker of eosinophilic airway inflammation. We therefore aimed to 
investigate differences in FENO in general populations of Sweden 
(Stockholm and Örebro), Finland (Helsinki), and Estonia (Narva and 
Saaremaa), and the associations of FENO with asthma, asthma symptoms, 
smoking and skin prick test (SPT) findings to common allergens, thus 
assessing the west-east disparity hypothesis of allergic diseases. 
2. Materials and methods 
Random samples of general populations in five areas from Sweden, 
Finland and Estonia answered questionnaires on respiratory symptoms 
and diseases in 1995–1996, as part of a cross-sectional study. One to five 
years later, at the turn to the 21st century, random samples from these 
cohorts were invited to clinical examinations in all participating centres 
(Fig. 1), including measurements of FENO, lung function and SPT, and a 
structured clinical interview on symptoms of respiratory diseases. 
2.1. Study populations 
In 1995 and 1996, we surveyed 34 951 adults in general populations 
in Sweden, Finland and Estonia with a postal questionnaire (see flow-
chart in Fig. 2 and anthropometric and spirometric data in Table 1) sent 
to individuals randomised in 10-year-age cohorts from the Population 
Register Centres, taking into account the overall gender distribution in 
each local population. The postal questionnaire was answered by 27 697 
(79% of invited) subjects: 6062 (76%) in Helsinki, 5754 (72%) in 
Stockholm, 6784 (84%) in Örebro, 4325 (78%) in Narva, and 4808 
(89%) in Saaremaa. Among all these, a random sample (stratified by age 
and gender) of 4944 individuals (18% of those who replied to the postal 
questionnaires) were invited to a clinical examination. A total of 2658 
(54% of invited) volunteers participated: 643 (54%) in Helsinki, 443 
(37%) in Stockholm, 719 (60%) in Örebro, 402 (60%) in Narva, and 451 
(67%) in Saaremaa. We further randomised these subjects and per-
formed FENO measurements, and skin prick testing around the turn of the 
millennium (1997–2003) on 1669 participants. We included for this 
study a total of 1498 individuals with valid FENO measurements aged 
20–60 years, among whom 92% had valid SPTs. 
2.2. Questionnaire and clinical interview 
We selected 11 questions from the clinical interview, including those 
questions with reference to self-reported or diagnosed obstructive res-
piratory diseases, asthma symptoms, asthma medication, smoking, and 
self-reported allergic rhinitis or conjunctivitis. The postal questionnaire 
was based on the OLIN (Obstructive Lung Diseases in Northern Sweden) 
research project and further on the British Medical Research Council and 
Tucson questionnaires [3]. The clinical interview was based on the 
former postal questionnaire, but augmented with detailed questions of 
symptoms, medication, and possible risk factors for obstructive airway 
diseases and allergy. Translations of the questionnaire were available in 
all native languages (Finnish, Swedish, Estonian, and Russian). Inde-
pendent translations of the questionnaires from Swedish to other lan-
guages were produced by bilingual translators who were aware of the 
objective of the study and had expertise in the study topic. 
Fig. 1. Map of the FinEsS research centres in Sweden, Finland and Estonia. Map 
tiles by Stamen Design, under CC BY 3.0. Data by OpenStreetMap, under ODbL. 
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2.3. Definitions 
The definitions presented below were based on affirmative answers 
to each question. 
Asthma: have you ever had asthma? 
Asthma diagnosis: Have you been diagnosed with asthma by a 
physician? 
Childhood asthma: Have you had asthma during childhood or had a 
wheeze during breathing in early childhood? 
Chronic obstructive pulmonary disease (COPD) diagnosis: Have you 
been diagnosed with chronic bronchitis or emphysema by a physician? 
Current smoker: are you a current smoker? 
Allergic rhinitis or conjunctivitis (ARC): Have you or have you had hay 
fever (allergic rhinitis) or allergic eye inflammation? 
Asthma symptoms during the last year: Have you had any asthma 
symptoms during the last 12 months? 
Nightly asthma symptoms last year: Have you ever been woken up 
during the night or early morning by an attack of shortness of breath 
with wheezing? If yes, has this happened during the last 12 months? 
Asthma medication during the last year: Have you used any asthma 
medicines during the last 12 months? 
Inhaled corticosteroids (ICS) last year: Have you used inhaled corti-
costeroids during the last 12 months (List of national commercial 
names)? 
Short acting β-agonists (SABA) last year: Have you used inhaled short 
acting β-agonists during the last 12 months (List of national commercial 
names)? 
2.4. FENO measurements 
FENO was measured according to the European Respiratory Society 
(ERS) guidelines [17], but the expiratory flow rate varied between the 
study centres. All participating centres employed a chemiluminescence 
nitric oxide (NO) analyser, Sievers 270B (Boulder, CO, USA). The de-
vices were calibrated daily (two-point calibration). The gas used for 
inhalation was NO-free synthetic air. The exhalation was visually 
controlled and flow resistors were used (Hans Rudolph Inc., Shawnee, 
KS, USA) in order to control the target flow range and to close the soft 
palate. The expiratory flow rates were: 250 mL/s in Stockholm and 
Örebro, 50 mL/s in Helsinki, and 100 mL/s in Narva and Saaremaa. The 
exhalation time was at least 6 s. The mean FENO obtained for analysis 
comprised a mean value of three consecutive end-of-exhalation plateau 
determinations. No nose-clips were used for the manoeuvres, but 
mouthwashes were performed prior to the measurements: in Helsinki 
with carbonated water, and in other centres with tap water, in order to 
reduce oral NO contamination [18,19]. 
Since the study centres utilised different expiratory flows in FENO 
measurements, all FENO values had to be converted to values with a 50 
mL/s flow, the recommended value by the American Thoracic Society 
(ATS) and ERS [20], for comparison between the study centres. We used 
a conversion model developed by Lassmann-Klee et al. [21], which ac-
counts for different flow-rates and different mouthwashes. 
We selected a FENO value of ≥25 ppb as an intermediate cut-off value 
according to ATS and ERS [22,23]. 
2.5. Skin prick tests 
We tested 92% of the participants with SPTs for the following al-
lergens: dog, cat, horse, timothy-grass, birch, mugwort, moulds (Alter-
naria alternata, Cladosporium herbarum), and house dust mites 
(Dermatophagoides pteronyssinus, Dermatophagoides farinae). The testing 
protocol was previously described elsewhere [24]. All centres, apart 
from Stockholm, arranged additional testing for storage mites (Lep-
idoglyphus destructor, Acarus siro), cow, cockroach (Blatella germanica), 
and latex. We defined a volunteer as atopic, if at least one positive SPT 
was observed, i.e. a skin reaction of ≥3 mm, after rejecting cases with 
dermographism [25]. 
2.6. Spirometry 
We used different spirometers in the participating centres: Ohio 
spirometer (Stockholm), Volugraph 2000 and Vitalograph (Örebro), 
SensorMedix Vmax22 (Helsinki) and Mijnhardt Vicatest 5 (Narva and 
Saaremaa). We acquired forced expiratory volume in 1 s (FEV1) only 
(Table 1). The highest value of three acceptable FEV1 values was 
recorded. 
Fig. 2. Flowchart of population selection in Finland, Sweden and Estonia (FinEsS). Presented as n, (%*) percentage of invited, or (%) percentage of total. Postal 
questionnaire (PQ), fractional exhaled nitric oxide (FENO). 
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2.7. Statistics 
All statistical tests were performed in R [26]. Due to a non-normal 
distribution of FENO in the general population, we tested the differ-
ences between the centres and countries with a Kruskal–Wallis test, with 
a post-hoc Dunn’s test for multiple comparison and Holm’s adjustment. 
FENO distributions in two-group variables were compared with a 
Wilcoxon–Mann–Whitney–Test for independent groups. 
We calculated raw odds ratios (OR) with a two-by-two table, the 95% 
confidence intervals (CI) using the method number ten by Newcombe 
[27] and corresponding p values with Pearson’s χ2 test with Yates’ 
continuity correction. The adjusted ORs were calculated by binary lo-
gistic regression. Within the binary logistic regression, we tested the 
multiple parameters of the study centre variable with Wald χ2 statistics. 
The best fitting models were selected by using the Akaike information 
criterion (AIC). 
We calculated a minimum sample size of n = 1232 for a binary lo-
gistic regression when considering an odds ratio of 1.5 for an event and a 
prevalence of 4%, according to Hsieh et al. [28]. 
2.8. Ethics 
The study was approved by the Ethics Committee of Department of 
Medicine of Helsinki University Hospital, the Tallinn Ethics Committee 
in Estonia and the Swedish Ethical Review Authority. All individuals 
filled in a written informed consent form attached to the structured 
interview. 
3. Results 
Totally, 1498 persons were included in the analyses from five cen-
tres. Age, height, weight, BMI, and FEV1 results were similar in the study 
centres (Table 1). 
3.1. Prevalence of symptoms and diagnoses 
The diagnoses, respiratory symptoms, and median FENO varied 
significantly between the areas (Table 2). The population in Stockholm 
had a high prevalence of asthma (13%), asthma diagnosis (11%), asthma 
symptoms last year (13%) and asthma drug use (ICS 9%, SABA 10%), 
while the population in Saaremaa had the lowest prevalences of asthma 
(3%), asthma diagnosis (2%), asthma symptoms, and asthma drug use. 
We found the highest prevalence of COPD diagnosis (18%) and current 
smokers (41%) in the population of Narva. The studied sample from 
Helsinki had the highest prevalence of allergic rhinitis or conjunctivitis 
(ARC) (40%) and atopy (49%). 
3.2. Fractional exhaled nitric oxide: FENO 
The median (interquartile range (IQR)) FENO was 14.0 (10.5) ppb in 
the pooled sample, and 15.5 (9.3) in Sweden, 15.4 (13.6) in Finland and 
12.5 (9.6) in Estonia (Kruskal–Wallis test, p < 0.001). The post-hoc 
analysis showed differences in median FENO between Estonia and the 
other countries (p < 0.001). Median FENO varied significantly between 
the centres (p < 0.001) (Fig. 3). We found lower median FENO (p <
0.001) values in Estonian centres, with differences between Narva and 
Helsinki (p < 0.001), Narva and Stockholm (p = 0.001), and Narva and 
Örebro (p < 0.001); and as well as significant differences between 
Saaremaa and Helsinki (p = 0.002), and Saaremaa and Örebro (p <
0.001). 
3.3. Between country comparisons for asthma 
The likelihood of having asthma was higher in Sweden and Finland 
than in Estonia, with crude OR 2.39(1.48-3.85) and 2.0(1.12-3.58), 
respectively. Comparing Sweden with Finland, we found similar likeli-
hood of having asthma, crude OR 1.19(0.71-2.0). 
3.4. FENO and asthma 
We found that self-reported asthma was associated with FENO ≥25 
ppb, OR 3.91(2.39-6.32), after adjusting for SPT result, smoking, gender 
and study centre in a binary logistic regression model (Fig. 4) (Model can 
be found in the Appendix). Within this same model, we found that the 
overall effect of the study centre in general (p < 0.01) was a significant 
factor associated with asthma. Analysing the differences between the 
study centres within the model, we found that compared to Saaremaa, 
the likelihood of having asthma was higher in Helsinki OR 2.40(1.04- 
6.02), Narva OR 2.45(1.05-6.19), Örebro OR 3.38(1.59-8.09), and 
Stockholm OR 5.54(2.18-14.79). Within the model, asthma was asso-
ciated with a positive SPT result, OR 3.19(2.02-5.11), but not with 
smoking OR 0.87(0.50-1.46) or gender OR 0.81(0.51-1.27), in the whole 
population. 
In the total pooled sample, the mean FENO was higher in participants 
with asthma (27 ppb) than without asthma (16 ppb) (p < 0.001), see 
Table 3. When stratifying for current smoking status, the mean FENO was 
higher in non-smokers, than in smokers (p < 0.01), both in asthmatics 
and in non-asthmatics. Further stratification revealed a higher mean 
FENO in atopic asthmatic individuals, than in non-asthmatics (p < 0.001) 
with atopy. Analogously, non-atopic asthmatic individuals had a higher 
mean FENO compared to non-asthmatics (p = 0.016) without atopy. 
3.5. FENO ≥25 ppb 
In the pooled sample, individuals with FENO ≥25 ppb were more 
likely to have atopy, self-reported asthma, physician diagnosed asthma, 
and allergic rhinitis (Table 4). Participants with FENO ≥25 ppb were 
more likely to report asthma symptoms, nightly symptoms, ICS use, and 
SABA use, in the previous year. Current smokers were more likely to 
have a FENO result <25 ppb. A result of FENO ≥25 ppb was not associated 
with COPD diagnosis or childhood asthma. 
The prevalence of FENO ≥25 ppb in the pooled sample was 14.6%, 
with 14.7% in Sweden, 21.4% in Finland, and 11.2% in Estonia. In the 
centres, the prevalence of FENO ≥25 ppb was 10.6% in Stockholm, 16.6% 
in Örebro, 21.4% in Helsinki, 11.4% in Narva, and 11.1% in Saaremaa. 
The ORs (95% CIs) for FENO ≥25 ppb, compared to Finland, were 
Table 1 
Anthropometric data and forced expiratory volume in 1 s (FEV1) in adult general populations of Stockholm, Örebro, Helsinki, Narva, and Saaremaa.    
Total Stockholm Örebro Helsinki Narva Saaremaa  
n 1498 179 391 295 281 352 
Gender f/m 824/674 99/80 199/192 174/121 162/119 190/162  
% 55/45 55/45 51/49 59/41 58/42 54/46 
Age (years) mean (sd) 40.9 (10.9) 39.3 (10.0) 42.1 (10.8) 40.9 (10.2) 40.2 (11.6) 41.0 (11.4) 
Height (cm) mean (sd) 171.1 (9.3) 172.9 (9.6) 172.2 (9.2) 170.0 (9.3) 168.6 (8.7) 171.7 (9.3) 
Weight (kg) mean (sd) 75.3 (14.7) 72.7 (13.5) 75.5 (13.8) 75.2 (16.2) 73.7 (13.5) 77.6 (15.7) 
BMI(kg/m2) mean (sd) 25.7 (4.5) 24.2 (3.5) 25.4 (3.9) 26.0 (5.0) 25.9 (4.4) 26.3 (5.0) 
FEV1 (L) mean (sd) 3.4 (0.9) 3.7 (0.8) 3.2 (0.8) 3.3 (0.9) 3.4 (0.9) 3.6 (0.9) 
f = female, m = male, sd = standard deviation. 
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0.60 (0.41–0.89) in Sweden and 0.48 (0.33–0.72) in Estonia, and 
adjusted for positive SPT 1.52 (1.11–2.07), smoking 0.33 (0.22–0.49), 
and male gender 1.36 (1–1.85). Similarly, compared to Helsinki, the 
adjusted OR for FENO ≥25 ppb was 0.42 (0.21–0.81) in Stockholm, 0.65 
(0.43–0.98) in Örebro, 0.53 (0.32–0.84) in Narva and 0.45 (0.28–0.71) 
in Saaremaa. 
4. Discussion 
We observed a west–east gradient of FENO levels and prevalences of 
asthma and asthma symptoms in the studied populations from Sweden, 
Finland and Estonia. In the pooled samples, we found a higher median 
FENO in Sweden and Finland compared to Estonia. The Estonian centres 
had a lower median FENO compared to Swedish and Finnish centres. The 
Estonian populations and the pooled Estonian sample also had lower 
adjusted ORs for asthma. 
Previous investigations on these Nordic populations hypothesised 
diagnostic differences and labelling of asthma as potential explanations 
for the lower prevalence of asthma and its symptoms in Estonia [14], as 
well as possible low physician diagnosis rates [11]. Nevertheless, we 
found significantly different FENO levels in the regions studied, sup-
porting the view, that there is a real disparity in asthma prevalences 
between the studied centres, reflecting differences in allergic airway 
diseases. The reasons for the west–east gradient in FENO and asthma 
prevalence may be based, for example, on differences in genetic, 
geographical, environmental, occupational and socio-economical risk 
factors and lifestyle, and on protective factors, like rural living. A pre-
vious comparison between Uppsala in Sweden and Tartu in Estonia 
found a lower prevalence of atopy, and a lower prevalence of 
pollen-associated asthma symptoms in Estonia than in Sweden [29]. 
However, a previous FinEsS study found, apart from similar prevalence 
of sensitisation in Sweden, Finland and Estonia, a deviant sensitisation 
pattern: storage mites and cockroach were major sensitisers in Estonia 
[30], while sensitisation in Finland and Sweden was mainly attributable 
to pollen and furry animals [24,31]. Moreover, marked differences in 
the sensitisation levels have been found between North Karelia in 
Finland and the Republic of Karelia in Russia, with higher asthma 
prevalence in Finnish Karelia [32]. Remarkably, another study in 
Uppsala and Tartu found lower mean eosinophilic cationic protein (ECP) 
blood levels, a biomarker of eosinophilic inflammation, in Tartu [33], 
further endorsing the findings of the present study. Farm living was 
previously found to reduce the risk for allergy and asthma development 
[6,34,[35]], and this could partly explain the lower asthma risk in 
Saaremaa, an Estonian island with a high degree of rurality. On the other 
hand, Narva is a highly industrialised and air-polluted area next to the 
Table 2 
Median FENO (interquartile range (IQR)) and prevalence of asthma, respiratory symptoms within the last year, and atopy in Stockholm, Örebro, Helsinki, Narva, and 
Saaremaa.    
Stockholm Örebro Helsinki Narva Saaremaa p 
FENO median (IQR)  14.4 (8.0) 15.7(10.1) 15.4 (13.6) 11.8 (8.6) 13.1 (9.5) <0.001†
% % % % %  
Ever asthma Yes 12.8 8.5 9.1 6.3 2.9 <0.001 
Asthma by MD Yes 11.4 7.8 7.2 5.4 2.3 <0.001 
Asthma in childhood Yes 8 8.6 7.3 1.8 6.4 <0.01 
Asthma symptoms Yes 13.4 9.2 12.5 6.1 2.6 <0.001 
Nightly symptoms Yes 7.3 4.9 1 6.4 4.3 <0.01 
Asthma medication Yes 12.3 6.9 9.2 4.6 2.3 <0.001 
ICS used Yes 8.9 4.1 5.1 1.1 0.6 <0.001 
Saba used Yes 10.1 5.9 4.4 3.6 2.3 <0.01 
Atopy Positive 21.2 33.5 48.5 37.7 25.8 <0.001 
Allergic rhinitis Yes 33 39.4 40 32.4 17.6 <0.001 
Current smoking Yes 37.2 22 37 40.5 34.1 <0.001 
COPD by MD Yes 2.9 1.31 2.8 17.8 9.2 <0.001 
MD = medical doctor, COPD = chronic obstructive pulmonary disease, ICS = inhaled corticosteroid, SABA = short-acting β2-agonist, bolded numbers represent the 
highest prevalence †p values calculated with Kruskal-Wallis test for the differences in FENO, for the others Pearson’s χ2 test for the interviews’ answers and atopy (skin 
prick tests). 
Fig. 3. Boxplot with fractional exhaled nitric oxide (FENO) values of general 
adult populations from the participating centres: Helsinki (n = 295), Stockholm 
(n = 179), Örebro (n = 391), Narva (n = 281), and Saaremaa (n = 352) grouped 
by countries. 
Fig. 4. Binary logistic regression model with asthma as outcome and FENO ≥25 
ppb, participating centre, gender, smoking, and atopy as predictors. Presented 
as odds ratio (OR) with 95% confidence intervals. Reference groups: FENO <25 
ppb, no atopy, Saaremaa, non-smoker and female. 
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Russian border, with an ethnic Russian majority [9], and high preva-
lences of smoking (40.5%) and COPD (17.8%). A recent study analysing 
the air concentrations of fine particles, benzene, and phenol, showed a 
similar prevalence of self-reported asthma in Narva, as in our present 
study [36]. The environmental factors, smoking and occupational con-
ditions could partly explain the low median FENO, since our analyses 
revealed a slightly higher likelihood of asthma in Narva compared to 
Saaremaa. 
Previous studies observed a decrease of FENO levels by current 
smoking [37–39], and others have also suggested a similar effect by past 
smoking [39,40]. An experimental study in lung epithelial cells 
discovered a possible mechanism for the effect of cigarette smoke on 
FENO production, down-regulation of an inducible nitric oxide synthase 
enzyme (iNOS) [41]. Our stratified analyses corroborate the lower FENO 
levels in smokers, independently of asthma or atopy. 
As expected, a FENO level ≥25 ppb was strongly associated with 
asthma in the pooled population. Likewise, a positive SPT result was 
associated with asthma. A previous study from an Icelandic population, 
in which FENO ≥25 ppb was positively associated with asthma and a 
positive SPT, found a similar prevalence of FENO ≥25 ppb as in our 
Finnish population [42]. 
Previously, atopy and smoking were found to be associated with FENO 
in Scandinavian populations [42–44]. Nevertheless, a previous investi-
gation in Helsinki could not find differences of FENO between SPT 
negative and SPT positive healthy asymptomatic non-smokers [45]. 
Thus, elevated FENO in atopic subjects indicates an allergic airway dis-
order. In concordance with a large study of FENO in Scandinavia [44], we 
showed here that atopic subjects frequently have elevated FENO levels 
regardless of smoking. 
This is, as far as we know, the largest multi-centre study on FENO in 
populations of Northern European countries, including skin prick testing 
and a structured interview. The study reflects the era after the Estonian 
Restoration of Independence and the end of the Soviet occupation dur-
ing the 1990’s, which apart from its historical importance, marks a 
change in lifestyle, occupational and socio-economical conditions. At 
the same time, Finland and Sweden were already immersed in a wes-
ternised lifestyle with a higher socio-economical status. This back-
ground gives unique possibilities to study the differences in the 
prevalences of asthma and atopy and to find out differences in FENO 
levels. Previously, an increase in atopic sensitisation was found after the 
German Reunification in schoolchildren in former East Germany during 
the 1990’s [2]. 
One strength of the study is, that self-reported parameters were 
compared with measured FENO and skin-prick test data. Weaknesses of 
the present study could be, apart from employing self-reported param-
eters, a possible selection bias through multiple inclusion steps and the 
differences in expiratory flows in the original FENO measurements. 
Nevertheless, we employed similar FENO devices and applied a validated 
conversion model to standardise FENO to the recommended expiratory 
flow of 50 mL/s [21] to obtain comparable values. The standardised 
FENO values are similar to those obtained in large general populations 
studies [46] and also by applying a reference equation to our pooled 
population [47]. The FENO value obtained in Örebro in the present study 
is in harmony with the values found in a general population study from 
Gothenburg in Sweden [44], which employed the recommended expi-
ratory flow of 50 mL/s. 
In conclusion, the median FENO was lower in the general adult pop-
ulations in Estonia, than in Sweden or Finland. We found that FENO 
followed a west-east gradient, parallel with the differences in asthma 
prevalence in the studied centres and a higher likelihood of asthma in 
western populations. The findings support the earlier west-east disparity 
hypothesis of allergic diseases. We also showed here that atopy and 
increased FENO values (≥25 ppb) were independently positively associ-
ated with asthma, confirming earlier studies. 
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Table 3 
Fractional exhaled nitric oxide (FENO) mean (SD) stratified by smoking and atopic status in participants with or without asthma.    
Asthmatics (n = 103) Non asthmatics (n = 1329) 
FENO (ppb) mean (sd) 27 (29) 16.3 (11)   
current non smoker current smoker current non smoker current smoker  
n (%) 80 (73%) 23 (22%) 903 (68%) 422 (32%) 
FENO (ppb) mean (sd) 29.8 (31.6) 17.1 (12.9) 18 (11.6) 12.8 (8.8) 
FENO ≥25 ppb % 32 (40%) 4 (17%) 142 (16%) 26 (6%)   
atopic non-atopic atopic non-atopic atopic non-atopic atopic non-atopic   
Σn = 67 Σn = 21 Σn = 841 Σn = 393  
n (%) 42 (63%) 25 (37%) 13 (62%) 8 (38%) 271 (32%) 570 (68%) 130 (33%) 263 (67%) 
FENO (ppb) mean (sd) 31.5 (37.3) 30.9 (22.5) 21.7 (14.9) 11.3 (7.1) 19.9 (14.2) 17 (9.8) 13.3 (11.4) 12.4 (7.4) 
FENO ≥25 ppb n (%) 17 (41%) 13 (52%) 3 (10%) 1 (13%) 53 (20%) 80 (14%) 10 (7.7%) 15 (6%) 
Data shown as n (%) or mean (standard deviation). 
Table 4 
Univariate crude odds ratio (with 95% confidence intervals) in the pooled 
sample for FENO ≥25 ppb and diagnosis, respiratory symptoms and medication 
within last year, and current smoking.    
Odds ratio Confidence Intervals p 
Ever asthma Yes 3.71 2.40–5.74 <0.001 
Asthma by MD Yes 2.78 1.74–4.44 <0.001 
Asthma in childhood Yes 1.35 0.78–2.33 0.358 
Asthma symptoms Yes 3.1 2.06–4.68 <0.001 
Nightly symptoms Yes 2.04 1.15–3.60 0.02 
Asthma medication Yes 3.22 2.05–5.05 <0.001 
ICS used Yes 2.48 1.34–4.60 0.005 
Saba used Yes 3.40 2.04–5.65 <0.001 
Atopy Positive 1.62 1.20–2.19 0.002 
Allergic rhinitis Yes 2.11 1.58–2.83 <0.001 
COPD by MD Yes 1.09 0.61–1.92 0.897 
Current smoking Yes 0.33 0.23–0.49 <0.001 
MD = medical doctor, COPD = chronic obstructive pulmonary disease, ICS =
inhaled corticosteroid, SABA = short-acting β2-agonist. 
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